Navigation Links
Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
Date:10/19/2009

SAN FRANCISCO, Oct. 19 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biotherapeutics company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to Jennerex's product JX-594 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. JX-594 is expected to enter a Phase 3 pivotal trial in the second half of 2010.

European Orphan Drug Designation encourages the development of products that demonstrate promise for the treatment of a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union. The designation criteria also specify that there is no other satisfactory therapy for that indication and that if JX-594 is shown to be effective in pivotal trials, it would represent a significant clinical benefit to HCC patients. Orphan Drug status for JX-594 entitles Jennerex to 10 year market exclusivity in Europe if the Market Authorization Application (MAA) is approved as well as potentially increasing reimbursement pricing. The designation also confers special benefits, including eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees during development or at the time of application for marketing approval.

"This designation is an important step in the development of a potential breakthrough treatment for this lethal disease," said David H. Kirn, M.D., President and Chief Executive Officer of Jennerex. "We look forward to working closely with the European regulatory authorities to complete the global development of JX-594 for the treatment of primary liver cancer."

About Hepatocellular Carcinoma

The treatment of advanced hepatocellular carcinoma represents a significant unmet medical need. HCC is responsible for about 90 percent of the primary malignant liver tumors in adults. Most cases of HCC are secondary to either a viral hepatic infection (hepatitis B or C) or cirrhosis (alcoholism being the most common cause of hepatic cirrhosis). The usual outcome for patients is poor, because only 10 to 20 percent of hepatocellular carcinomas can be removed completely using surgery. If the cancer cannot be completely removed, the disease is usually deadly within three to six months.

About Jennerex

Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594, currently in an international randomized Phase 2 clinical trial for patients with primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the Company's poxviruses in cancer cells. These products not only cause cancer cell lysis thereby killing through replication, they simultaneously shut-off the blood supply to tumors, as well as stimulating the body's immune response to the cancer. Jennerex, Inc. is headquartered in San Francisco and has manufacturing and research activities based at the Ottawa Hospital Research Institute in Ottawa, Canada. For more information about Jennerex and the Company's pipeline of three clinical-stage products, please visit www.jennerex.com.

SOURCE Jennerex, Inc.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 Tie-up with ... initiative to save newborns   Fortis ... & newborns in collaboration with Breast Milk Foundation (BMF), a ... Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit ... source for infants and should be available to babies deprived ...
(Date:4/27/2016)... FRANCISCO , April 27, 2016 ... reach over USD 2.14 billion by 2022, according ... Inc.       (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ... technological advancement affecting the efficiency and accuracy delivered ... the persistent demand for novel urinalysis instruments and ...
(Date:4/26/2016)... 26, 2016 US demand for infection ... 4.9 percent annually to $27.6 billion in 2020.  ... to decrease rates of healthcare-associated infections (HAIs) will ... and services.  Although declining, the overall rate of ... levels set by the CDC.  Recent statistics indicate ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... One way to ignore solid evidence is to ... But we toss the baby out with the bathwater when we ignore all studies ... higher-quality studies and otherwise making better use of education policy research. , “When readers ...
(Date:4/28/2016)... ... April 28, 2016 , ... The American Society ... Anzu®, developers of the AnzuMedical™ Knowledge Sharing and Collaboration Platform™ , today ... The platform is scheduled to launch in July 2016 and will be a ...
(Date:4/28/2016)... ... ... A first-time look at workers’ compensation claims in Kentucky found that total costs ... (WCRI) announced, and that costs per claim were stable between 2009 and 2014. ... that indemnity costs per claim and benefit delivery expenses per claim were typical of ...
(Date:4/28/2016)... ... April 28, 2016 , ... Metabolic Nutrition ... at this week’s 2016 Europa Games Get Fit and Sports Expo in ... the Europa Orlando Expo coming up April 29-30, was selected as the perfect event ...
(Date:4/28/2016)... St. Louis, MO (PRWEB) , ... April 28, 2016 , ... Denise McCormick Baich had ... stanza, in 2009 the poetry arrived again much like a tsunami and took on a ... people closest to her encouraged her to do more with it than just file it ...
Breaking Medicine News(10 mins):